396 related articles for article (PubMed ID: 25726735)
1. Molecular, Neurochemical, and Behavioral Hallmarks of Reserpine as a Model for Parkinson's Disease: New Perspectives to a Long-Standing Model.
Leão AH; Sarmento-Silva AJ; Santos JR; Ribeiro AM; Silva RH
Brain Pathol; 2015 Jul; 25(4):377-90. PubMed ID: 25726735
[TBL] [Abstract][Full Text] [Related]
2. Carvacrol prevents impairments in motor and neurochemical parameters in a model of progressive parkinsonism induced by reserpine.
Lins LCRF; Souza MF; Bispo JMM; Gois AM; Melo TCS; Andrade RAS; Quintans-Junior LJ; Ribeiro AM; Silva RH; Santos JR; Marchioro M
Brain Res Bull; 2018 May; 139():9-15. PubMed ID: 29378222
[TBL] [Abstract][Full Text] [Related]
3. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.
Duty S; Jenner P
Br J Pharmacol; 2011 Oct; 164(4):1357-91. PubMed ID: 21486284
[TBL] [Abstract][Full Text] [Related]
4. Effects of graphene oxide nanoparticles administration against reserpine-induced neurobehavioral damage and oxidative stress in an animal model of Parkinson's disease.
Oukhrib M; Tamegart L; Assafi A; Hejji L; Azzouz A; Villarejo LP; Haida M; Mohamed C; Gamrani H
Food Chem Toxicol; 2023 Aug; 178():113904. PubMed ID: 37356558
[TBL] [Abstract][Full Text] [Related]
5. The medical treatment of Parkinson disease from James Parkinson to George Cotzias.
Fahn S
Mov Disord; 2015 Jan; 30(1):4-18. PubMed ID: 25491387
[TBL] [Abstract][Full Text] [Related]
6. Repeated treatment with a low dose of reserpine as a progressive model of Parkinson's dementia.
Ikram H; Haleem DJ
Pak J Pharm Sci; 2019 Mar; 32(2):555-562. PubMed ID: 31081766
[TBL] [Abstract][Full Text] [Related]
7. Acute reserpine administration elicits long-term spontaneous oral dyskinesia.
Sussman AN; Tran-Nguyen LT; Neisewander JL
Eur J Pharmacol; 1997 Oct; 337(2-3):157-60. PubMed ID: 9430409
[TBL] [Abstract][Full Text] [Related]
8. Changes in the mesocorticolimbic pathway after low dose reserpine-treatment in Wistar and Spontaneously Hypertensive Rats (SHR): Implications for cognitive deficits in a progressive animal model for Parkinson's disease.
Leão AHFF; Meurer YSR; Freitas TA; Medeiros AM; Abílio VC; Izídio GS; Conceição IM; Ribeiro AM; Silva RH
Behav Brain Res; 2021 Jul; 410():113349. PubMed ID: 33971246
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the therapeutic potential of cerebrolysin and/or lithium in the male Wistar rat model of Parkinson's disease induced by reserpine.
Tharwat EK; Abdelaty AO; Abdelrahman AI; Elsaeed H; Elgohary A; El-Feky AS; Ebrahim YM; Sakraan A; Ismail HA; Khadrawy YA; Aboul Ezz HS; Noor NA; Fahmy HM; Mohammed HS; Mohammed FF; Radwan NM; Ahmed NA
Metab Brain Dis; 2023 Jun; 38(5):1513-1529. PubMed ID: 36847968
[TBL] [Abstract][Full Text] [Related]
10. Experimental models of Parkinson's disease: insights from many models.
Tolwani RJ; Jakowec MW; Petzinger GM; Green S; Waggie K
Lab Anim Sci; 1999 Aug; 49(4):363-71. PubMed ID: 10480640
[TBL] [Abstract][Full Text] [Related]
11. Botulinum neurotoxin A ameliorates depressive-like behavior in a reserpine-induced Parkinson's disease mouse model via suppressing hippocampal microglial engulfment and neuroinflammation.
Li Y; Yin Q; Li Q; Huo AR; Shen TT; Cao JQ; Liu CF; Liu T; Luo WF; Cong QF
Acta Pharmacol Sin; 2023 Jul; 44(7):1322-1336. PubMed ID: 36765267
[TBL] [Abstract][Full Text] [Related]
12. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
[TBL] [Abstract][Full Text] [Related]
13. Aging accentuates decrease in tyrosine hydroxylase immunoreactivity associated with the increase in the motor impairment in a model of reserpine-induced parkinsonism.
Melo JEC; Santos TFO; Santos RS; Franco HS; Monteiro MCN; Bispo JMM; Mendonça MS; Ribeiro AM; Silva RH; Gois AM; Marchioro M; Lins LCRF; Santos JR
J Chem Neuroanat; 2022 Nov; 125():102162. PubMed ID: 36115503
[TBL] [Abstract][Full Text] [Related]
14. Deuterium-substituted L-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by L-DOPA and an MAO-B inhibitor.
Malmlöf T; Feltmann K; Konradsson-Geuken Å; Schneider F; Alken RG; Svensson TH; Schilström B
J Neural Transm (Vienna); 2015 Feb; 122(2):259-72. PubMed ID: 24906468
[TBL] [Abstract][Full Text] [Related]
15. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
Lees AJ; Tolosa E; Olanow CW
Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
[TBL] [Abstract][Full Text] [Related]
16. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.
Shiozaki S; Ichikawa S; Nakamura J; Kitamura S; Yamada K; Kuwana Y
Psychopharmacology (Berl); 1999 Nov; 147(1):90-5. PubMed ID: 10591873
[TBL] [Abstract][Full Text] [Related]
17. Memory impairment induced by low doses of reserpine in rats: possible relationship with emotional processing deficits in Parkinson disease.
Fernandes VS; Ribeiro AM; Melo TG; Godinho M; Barbosa FF; Medeiros DS; Munguba H; Silva RH
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1479-83. PubMed ID: 18579275
[TBL] [Abstract][Full Text] [Related]
18. The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat.
Hill MP; Brotchie JM
Br J Pharmacol; 1999 Dec; 128(7):1577-85. PubMed ID: 10602339
[TBL] [Abstract][Full Text] [Related]
19. alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach.
Bazzu G; Calia G; Puggioni G; Spissu Y; Rocchitta G; Debetto P; Grigoletto J; Zusso M; Migheli R; Serra PA; Desole MS; Miele E
CNS Neurol Disord Drug Targets; 2010 Aug; 9(4):482-90. PubMed ID: 20522009
[TBL] [Abstract][Full Text] [Related]
20. Effect of N1-dansylspermine and Ro25,6981 on locomotor activity in naive mice and in the reserpinized mouse model of Parkinson's disease.
Devadasan C; Starr B; Doyle KM
Neuroreport; 2016 Dec; 27(17):1243-1247. PubMed ID: 27653937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
